In a study in the journal Diabetes Technology & Therapeutics (DTT), investigators evaluated biomarkers for cardiovascular ...

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...

The quip was seemingly a dig at Meghan Markle, who raised eyebrows in an episode of her divisive new Netflix show, With Love, ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

Tirzepatide and semaglutide offer long-term health benefits but are not cost-effective, according to a study publi ...

In a new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT), investigators evaluated biomarkers for ...

Among all antiobesity medications, the incremental cost-effectiveness ratios were $197,023 and $467,676 per quality-adjusted life-year for tirzepatide and semaglutide, respectively. HealthDay News ...

It is not sold by Eli Lilly in any oral format. Lexaria's Study was designed to discover whether the active drug within Zepbound® - tirzepatide - could be administered using Lexaria's patented ...

University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity ...

The Outsourcing Facilities Association is appealing a ruling that rejected their request for an injunction against the FDA’s ...